Peregrine Pharma (PPHM) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2015 Financial Results and Recent Developments
March 12, 2015 4:00 PM EDT- SUNRISE Phase III Lung Cancer Trial On Track to Complete Enrollment by Calendar Year-End -
- Encouraging and Consistent Data from Immuno-Oncology Development Program Continue to Support Bavituximab's Immunostimulatory Mechanism -
- Avid Bioservices Increases Revenue Guidance to Between $23 and $25 Million for Full Fiscal Year 2015 Based on Strong Demand for Services
TUSTIN, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) (Nasdaq: PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology... More
